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CANCER INCIDENCE RATE AND AGING
In 1825, Gompertz [1] reported that the  mortality 
increases exponentially with age (Gompertz law 
of mortality). At present, this law is still true. Fig. 1 
shows the recent data on death rates for specified age 
groups (taking into account both sexes of all races) 
that were obtained from the survey of the chances for 
death in 2006 for the entire population of the United 
States (these data are from the National Center for 
Health Statistics, USA [2]). The fact that the mortality 
increases exponentially with age indicates that the 
progressive accumulation of diverse adverse changes 
within the life span (these changes increase the risk of 
death) is likely to predetermine the rate of aging. As 
Harman [3] stated, “the rate of aging is low early in life, 
but rapidly increases with age due to the exponential 
nature of the process”. Obviously, the aging process 
depends upon two components of its regulation: 1) 
intrinsic (i.e., genetic); 2) extrinsic, which includes 
lifestyle factors and environmental exposures.
Advancing age is known as a high risk factor for 
cancer. The relevance of aging to the risk of overall 
cancer is likely to be supported by the fact that the 
cancer risk exponentially increases with age despite 
the age-specific occurrence of some kinds of cancer. 
According to the data from the U.S. National Cancer In-
stitute (NCI) Surveillance, Epidemiology, and End Re-
sults (SEER) Program [4, 5], the cancer risk increases 
exponentially up to a certain age (70–74 years), then 
decelerates (75−84 years) and eventually declines 
(≥ 85 years) (Fig. 2). It should be noted that ≈ 60% 
of newly diagnosed malignancies and ≈ 70% of all 
cancer deaths occur in persons aged ≥ 65 years [4, 
5]. More than 70% of the mortality associated with 
many cancers including prostate, bladder, colon, 
uterus, pancreas, stomach, rectum and lung occurs 
in persons aged ≥ 65 years [4−6]. Deceleration and 
decline of the cancer incidence rate at older ages is 
an interesting but not fully understood phenomenon. 
It seems that the large amount of age-associated 
changes accumulated by older ages (≥ 75 years; see 
Fig. 2) somehow reduces the probability of cancer 
occurrence and/or its detection. Driver et al. [7] have 
recently proposed that the decrease in incidence of 
cancer late in life is largely due to a substantial amount 
of undiagnosed disease. On the other hand, it has 
been reasonably hypothesized that the age-related 
decline of the rate of cell proliferation together with 
accumulation of senescent (non-proliferating) cells 
may lead to the reduction in the number of newly trans-
formed cells at older ages, thereby contributing to this 
aforementioned phenomenon [8]. A late-life mortality 
rate plateau that has been theoretically predicted [9, 
10] may be relevant to deceleration and decline of the 
cancer incidence rate at older ages.
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Fig. 1. Death rates for specified age groups (both sexes of 
all races) obtained from the survey of the chances for death 
in  2006 for the entire population of the United States. Elevated 
mortality rate in children of the age group of 0−4 years can be 
explained by the fact that children under 1 year die quite fre-
quently (death rate: 690.7) [2]
It should be pointed out that in the United States, 
for instance, among the causes of death in the current 
millennium, malignant neoplasms remain to be second 
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after cardiovascular disease (in 2006, cancers were 
23.1%, while cardiovascular disease was 26.0% [2]). 
Interestingly, according to the annual reports of the 
U.S. National Center for Health Statistics [2], the mor-
tality rate for cardiovascular disease steadily declines 
(≈ 0.5% every year), while the mortality rate for cancers 
remains unchanged, so one can predict that cancers 
by 2013 will be the number one cause of death.
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Fig. 2. Cancer incidence rates for specified age groups (both sexes 
of all races) based on NCI SEER program data of 1994–1998 [4, 5]
TELOMERES: THEIR ROLE IN CELLULAR 
SENESCENCE AND TUMORIGENESIS
The fact that the cancer incidence rate progresses 
with advancing age indicates that the mechanisms of 
tumorigenesis and aging somehow intersect. Dysfunc-
tional (shortened) telomeres appear to play a key role at 
the aging-cancer interface. In the beginning of 1990th it 
has been reported that the length of telomeres markedly 
decreases with advancing age and increasing passage of 
cell culture [11, 12]. At present, attrition of telomeres is a 
significant molecular biomarker of aging. Telomeres are 
known as nucleoprotein structures at the extreme ends of 
linear chromosomes, whose length (telomeric length) is a 
critical factor in maintaining genomic stability. Telomeric 
DNA, which does not contain protein-encoding genes, 
is composed of G-rich hexanucleotide repeats that have 
(TTAGGG)n sequence. Incomplete and inefficient (due to 
accumulation of telomeric DNA damage) end replication 
may contribute to telomere shortening [13, 14]. Repair of 
DNA (including telomeric DNA) appears to decline with 
aging [14, 15]. Telomeres shorten to a certain critical size, 
and this event signals cells to enter an irreversible growth 
arrest (i.e., cellular senescence) that may contribute to the 
aging of a whole organism. In most instances cells become 
senescent before they accumulate enough mutations to 
be cancerous, (this, in part, can explain deceleration and 
decline of the cancer incidence rate at older ages). The 
growth arrest induced by shortened telomeres may be a 
potent anti-cancer mechanism. It has been  reasonably 
noted that the starting point for telomere length in somatic 
cells is the length of telomeres in germ line cells of the 
individual or species, and this parameter is and must be 
strictly conserved in order to maintain viability of the spe-
cies [16]. The rate of telomere shortening is not necessarily 
a constant function of cell division.  In i n vitro maintained 
normal human cells the rate of telomere shortening may 
vary from 50 to 100 bp per cell division (“normative” 
telomere loss [16]) [17]. A permanent loss of telomeric 
DNA with each cell division is primarily because of the 
lagging strand of DNA synthesis cannot replicate the 
extreme 3  end of the chromosome (the “end replica-
tion problem”) [13]. Short telomeres in peripheral blood 
leucocytes have been reported to be associated not 
only with risks of cancer and cardiovascular disease, 
but also with mortality from them [18−20].
The integrity of telomeres is maintained, at least in 
part, by the ribonucleoprotein enzyme telomerase [21, 
22]. Telomerase activity is present in almost all human 
tumors but not in adjacent normal cells [23, 24]. It is 
growth-regulated, since it correlates with cell proliferation 
in both normal tissues and tumors [25]. The expression 
of telomerase activity does not necessarily correlate 
with the length of telomeres. In some mitotically active 
normal somatic cells telomeres become shorter with 
each cell division cycle even though telomerase activity 
is still  present [26]. Although most tumors do express 
telomerase activity, their telomeres are usually not as long 
as in normal tissues with lack of cell proliferation [25]. 
Activation of telomerase that is important in maintain-
ing telomere length stability may be necessary for the 
sustained growth of most tumors. Telomerase activity 
appears to be a promising diagnostic and prognostic 
marker of cancer [25, 27−29]. Nevertheless,  telomerase 
expression alone is not the inciting event in the trans-
formation to neoplasia. This is based on the fact that 
introduction and expression of telomerase do not induce 
a transformed phenotype [30, 31].
Although telomerase as well as telomeres plays 
an important role at the aging-cancer interface [32, 
33], the mechanism that can trigger tumorigenesis 
due to aging remains largely unknown. Most normal 
cells respond to dysfunctional telomeres by mounting 
a senescence response that requires the function of 
both pRb and p53, but another possible consequence 
of telomere dysfunction (absence of the senescence 
checkpoint and p53 function) is genomic instability, 
which is believed to be an early event in tumorigenesis 
[33, 34]. Thus, cellular senescence may be a “double-
edged sword” in this regard (i.e., pro- and anti-tumor-
igenic roles). Interestingly, dysfunctional telomeres 
can induce a DNA damage response that involves 
their association with DNA damage response factors 
(53BP1, γ-H2AX, Rad17, ATM, and Mre11) [35]. The 
domain of telomere-associated DNA damage factors 
is often referred as a telomere dysfunction-induced 
focus (TIF). TIFs containing multiple DNA damage 
response factors have been found to be assembled 
in a subset of senescent cells and signaled through 
ATM to p53, upregulating p21 and causing G1-phase 
arrest [36]. Senescent cells displaying dysfunctional 
telomeres (i.e., TIF-positive cells) have been found 
to accumulate with increasing age in dermal fibro-
blasts of skin biopsies of aging baboons [37], which 
like humans have a relatively long life span and show 
age-dependent telomere shortening [38]. It should 
be pointed out that the number of TIF-positive cells in 
this study accumulated exponentially with increasing 
age, reaching a value of 15−20% in very old (25−30 yr) 
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animals [37]. Probably, this finding is the first strong 
evidence of progressive (exponential) accumulation 
of age-related changes at the cellular level. The expo-
nential character of telomere dysfunction associated 
cellular senescence that was observed in primates 
is likely to take place in humans and contribute to an 
exponential increase of mortality and cancer incidence 
rates with  advancing age (see Fig. 1 and 2, respec-
tively). In senescent cells, in addition to the damage 
to telomeric DNA, the damage may also occur to non-
telomeric main DNA that contains protein-encoding 
genes. According to another finding by Herbig  et al. 
[37], in senescent dermal fibroblasts ≈ 30% of nuclear 
foci containing 53BP1 (one of the markers of DNA 
double-strand break) do no co-localize with telomeric 
DNA. If the double-strand break misrepaired or left un-
rejoined, it can cause transformation or cell death [39]. 
Telomere dysfunction has been reported to impair 
DNA repair [40], a finding that could help explain the 
persistence of DNA damage nuclear foci associated 
with non-telomeric DNA [37].
Finally, cellular senescence may not be caused due 
exclusively to replicative exhaustion. Oxidative stress 
appears to increase the rate of telomere shortening 
as evidenced from telomere-specific accumulation of 
DNA damage induced by reactive oxygen species [41]. 
Interestingly, accelerated telomere shortening has 
been found to be a function of response to life stress, 
namely to psychological stress, which is significantly 
associated with oxidative damage [42].
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